15 June 2022
EMA/CAT/275668/2022
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 11-13 May 2022

Chair: Martina Schuessler-Lenz; Vice-Chair: Ilona Reischl

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in these minutes are considered commercially confidential or sensitive and therefore not disclosed. Regarding intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Vice-Chairperson opened the meeting by welcoming all participants. Due to the coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda points.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The CAT agenda for 11-13 May 2022 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 11-13 April 2022 meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

2.1.1. Eladocagene exuparvovec - Orphan - EMEA/H/C/005352

PTC Therapeutics International Limited; treatment of aromatic L-amino acid decarboxylase (AADC) deficiency

Scope: Opinion

Action: for adoption

Oral explanation on 11.04.2022. List of Outstanding Issues adopted on 05.11.2021,

16.04.2021. List of Questions adopted on 20.05.2020.

The Rapporteur presented the updated assessment report: the post-authorisation studies were highlighted. Feedback was provided from the BWP discussion on the quality part of the application. Outstanding quality issues are reflected in the recommendation and the Annex II condition. CAT discussed the product information and agreed on a rewording of section 2.1.

CAT adopted by consensus a positive draft opinion recommending a marketing authorisation under exceptional circumstances. The Norwegian member was in agreement.

The CAT draft opinion and the CAT assessment report will be forwarded to CHMP for adoption.

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

2.8.1. Autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: withdrawal of marketing authorisation application. Withdrawal letter dated 02.05.2022.

Action: for information

Oral explanation on 11.04.2022. List of Outstanding Issues adopted on 16.07.2021. List of Questions adopted on 22.01.2021.

EMA informed the CAT that a formal withdrawal letter was received. The letter together with the latest adopted CAT assessment report (Day 180 assessment of the responses to the list of outstanding issues) will be published on the EMA website, after removal of the commercial confidential information.

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0050

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

Scope: Quality. Opinion.

Action: for adoption

The opinion was adopted.

2.11.2. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0051

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Pharmacovigilance. Request for supplementary information

Submission of the final report from study 20180062: "Observational Research Study Report (ORSR)" listed as a category 3 study in the RMP. This is a multinational, non-interventional, cross-sectional survey study for patients aged ≥ 18 years who have received Imlygic at least once in the 3 months prior to completing the survey to evaluate the effectiveness of the patient-directed additional risk minimisation measures (aRMM). The primary objective of this study is to evaluate patients' knowledge levels of the key messages included in the Patient Safety Brochure among patients who receive Imlygic.

Action: for adoption

The request for supplementary information was adopted.

2.11.3. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0052/G

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

Scope: Quality. Request for supplementary information.

Action: for adoption

The request for supplementary information was adopted.

2.11.4. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0053

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Clinical. Request for supplementary information

Submission of the final report from study CCTL019H2301 (BELINDA) listed as an obligation in the Annex II of the Product Information. This is a randomised open-label parallel-group multicentre phase III trial to evaluate the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory B-cell aggressive non-Hodgkin lymphoma (NHL) after failure of rituximab and anthracycline containing first-line immune-chemotherapy. Annex II is updated accordingly.

Action: for adoption

The Rapporteur presented the assessment of the final report of the Belinda study.

The request for supplementary information was adopted.

2.11.5. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0046

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, PRAC Rapporteur: Anette Kirstine Stark

Scope: Clinical. Request for Supplementary Information

Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) for Yescarta; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.3 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the product information with minor editorial changes.

Action: for adoption

Request for supplementary information adopted on 18.02.2022.

The Rapporteur presented the assessment of the responses to the Request for Supplementary Information. A second Request for supplementary information was adopted.

2.11.6. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0020/G

Novartis Gene Therapies EU Limited

Rapporteur: Carla Herberts

Scope: Quality. Opinion

Action: for adoption

Request for Supplementary Information adopted on 18.03.2022, 10.12.2021.

The opinion was adopted.

2.11.7. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0024

Novartis Gene Therapies EU Limited

Rapporteur: Carla Herberts

Scope: Quality and clinical. Opinion

Submission of an evaluation of the finished product specifications, in accordance with the obligation in the Annex IID of the Product Information (ANX 004), to be undertaken when primary and key secondary endpoint data from additional patients with 2 copies of survival motor neuron 2 (SMN2) are available (i.e. completion of CL-302 and CL-304 cohort 1). Annex II is updated accordingly.

Action: for adoption

Request for Supplementary Information adopted on 18.03.2022.

The opinion was adopted.

2.11.8. Yescarta - axicabtagene ciloleucel; Tecartus - brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2247

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Quality. Request for Supplementary Information.

Action: for adoption

The request for supplementary information was adopted.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/007.2

Novartis Europharm Limited

Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang

Scope: Statistical analysis plan (SAP) amendment 1 / (CCTL019B2401) - The MAH is requested to respond to the request for supplementary information adopted with the outcome of ANX-7.1

Action: for adoption

The MAH proposed this change to remove European Society for Blood and Marrow Transplantation (EBMT) as data source. They will only use data from CIBMTR (US registry) for the post authorisation efficacy study. This is considered acceptable. The report was adopted.

2.13.2. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/ANX/002.2

Orchard Therapeutics (Netherlands) BV

Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

Scope: MAH Response to ANX-002.1 [LongTERM-MLD study protocol] as adopted in November 2021: in order to further characterise the long-term efficacy and safety of Libmeldy in children with late infantile or early juvenile forms of metachromatic leukodystrophy (MLD), the MAH shall conduct and submit the results of a prospective study based on data from a registry, according to an agreed protocol.

Action: for adoption

The Rapporteur informed the CAT that the protocol for the non-interventional post-authorisation efficacy study (PAES) has not been finalised. The report was adopted.

2.13.3. Tecartus - brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/MEA/005.2

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

Scope: MAH response to MEA 005.1 [Protocol, study no. KT-EU-472-5966] as adopted in December 2021 - Prescriber Survey: Assess the prescribers' understanding of the risks of KTE-X19. Evaluate the effectiveness of risk minimisation activities: HCP educational materials, and Patient Alert Card.

Action: for information

CAT was informed of the outcome of the PRAC discussion on this post-authorisation measure.

2.13.4. CAT recommendation to MAHs of CAR-T cell-based therapies with regards to long-term safety and efficacy follow-up studies using European Society for Blood and Marrow Transplantation (EBMT) as a data source

Scope: CAT/PRAC recommendations

Action: for information

CAT was informed that PRAC endorsed the proposal adopted by CAT at their April meeting.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:

-Start of the procedure:	16.05.2022
-EMA Coordinator's draft report:	25.05.2022
-CAT Coordinator's comments:	01.06.2022
-Revised scientific recommendation:	10.06.2022
-CAT's discussion of scientific recommendation:	17.06.2022

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Wharton's Jelly Derived Mesenchymal Stem Cells – allogeneic

Intended for the treatment of other specified inflammatory spondylopathies (non-radiographic axial spondyloarthritis, M46.8).

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.2. Autologous keratinocytes, fibroblasts

Intended for the treatment of partial deep dermal and full thickness burn wounds and reconstructive surgery.

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.3. Dopaminergic neuronal microtissues containing A9 TH+ (Tyrosine hydroxylase) dopaminergic mature neuron

Intended for the treatment of Parkinson's disease.

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Ex-vivo expanded autologous Wharton's Jelly derived mesenchymal stem cells (WJ-MSCs)

Intended for the treatment of autism spectrum disorder.

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 3 June 2022.

4.2.2. Autologous adipose tissue-derived stromal cell fraction devoid of mature adipocytes

Intended for the treatment of temporomandibular disorders.

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 3 June 2022.

4.2.3. Cultured human adipose derived stromal cells

Intended for the treatment of stress urinary incontinence in men after radical prostatectomy.

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 3 June 2022.

4.2.4. Human autologous tumour and hypoxia educated macrophages

Intended for the treatment of spinal cord injury.

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 3 June 2022.

4.3. Day 60 revised scientific recommendation (following list of questions)

4.3.1. Leukocyte and platelet rich plasma, autologous

Intended for the treatment of critical limb ischemia.

Scope: ATMP scientific recommendation

Action: for adoption

Awaiting responses from the applicant. Postponed until the June CAT meeting.

4.4. Finalisation of procedure

4.4.1. Autologous transduced CD8+ T cells expressing the Melanoma associated antigen 1-(MAGE-A1)-specific T cell receptor TCR 8001

Intended for the treatment of patients with MAGE-A1 expressing solid tumours.

Scope: The European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The ATMP classification report was adopted. The product does fulfil the definitions of a cell therapy medicinal product and a gene therapy medicinal product and is therefore classified as a gene therapy medicinal product as defined in Article 2(5) of Regulation (EC) No 1394/2007.

4.4.2. Suspension of VST cells

Intended for the treatment of adults and children with therapy-resistant viral infection after allogeneic hematopoietic stem cell transplantation.

Scope: The European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The ATMP classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product as defined in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.3. Adipose-derived stem cells

Intended for the treatment of type 2 diabetes mellitus, Treatment of cardiac and pulmonary complications after Covid-19.

Scope: The European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The ATMP classification report was adopted. The product does fulfil the definition of a advanced therapy medicinal product as defined in Article 2(1) of Regulation (EC) No 1394/2007. CAT considered that the applicant has not provided sufficient information to support the claimed mode of action of the product in the indications sought and therefore CAT concluded that the product is an ATMP, but did not decide yet if it is a tissue engineered product or a somatic cell therapy medicinal product.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	02-05.05.2022
- Appointment of CAT Peer Reviewers:	11-13.05.2022
- SAWP first reports:	30.05.2022
- CAT Peer Reviewer comments (NC/C):	03.06.2022
- CAT Peer Reviewer comments (Q):	08.06.2022
- Discussion at SAWP:	07-10.06.2022
- Discussion at CAT and feedback to SAWP:	16.06.2022

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	07-10.06.2022
- Appointment of CAT Peer Reviewers:	15-17.06.2022
- SAWP first reports:	27.06.2022
- CAT Peer Reviewer comments (NC,C):	01.07.2022
- CAT Peer reviewer comments (Q):	06.07.2022
- Discussion at SAWP:	04-07.07.2022
- Discussion at CAT and feedback to SAWP:	14.07.2022

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoOIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	02-05.2022
SAWP recommendation:	10.05.2022
CAT recommendation:	17.06.2022
CHMP adoption of report and final recommendation:	23.06.2022

6.3.2. Month 1 – Discussion of eligibility

No items

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

No items

7.1.2. Vote by proxy

No items

7.2. Coordination with EMA Scientific Committees

7.2.1. COMP expert meeting on orphan conditions in inherited retinal diseases

Action: for discussion

EMA informed the CAT on the scope of the expert meeting. Dariusz Sladowksi will join this expert meeting.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Procedure on ATMP scientific advice and BWP interaction

Scope: procedure for interactions with BWP on scientific advice and timing/role of CAT peer review

Action: for adoption

The updated document, incorporating (where possible) the comments received from Barbara Bonamassa and Kristyna Rehorova Hradilkova, was presented. The new procedure was agreed and will be reviewed (and if needed further adapted) in October/November 2022.

B. Bonamassa reported from her experience this month with quality scientific advice (SA): a couple of points will be clarified with the BWP secretariat.

7.3.2. Routine GCP inspections selection – proposal to lift restrictions on the applications to be considered

Action: for information

CAT noted the lifting of the restrictions to conduct routine GCP inspections.

7.3.3. Embedding the outcome of GCP inspections into the benefit/risk assessment and modernisation of the inspection process

GCP WG: Jayne Crowe

Scope: Bringing to attention the GCP survey for assessors for the purpose of benchmarking awareness of GCP guidance within the regulatory network.

Action: for information

CAT noted the GCP survey that is open for comments until 30 May 2022.

7.4. Cooperation with the EU regulatory network

7.4.1. Revision of the EU pharmaceutical legislation (Directive 2001/83/EC and Regulation (EC) No 726/2004)

CAT: Martina Schüssler-Lenz, Sol Ruiz, Alessandro Aiuti

Action: for information

CAT was briefed of the discussions that took place at the April CHMP plenary meeting and the May CHMP PROM.

7.4.2. Revision of the EU legislation on blood, tissues and cells (BTC)

CAT: Martina Schüssler-Lenz

Scope: Update from the European Commission representative on the status of the BTC proposal

Action: for discussion

The Commission representative informed the CAT of the progress on the Commission proposal for the BTC legislation revision: the proposal will be published shortly. There were some reflections on the future interactions between the different sectors (medicinal products, devices and BTC).

It was proposed to invite the Commission representative again, once the Commission's proposal is published.

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Martina Schuessler-Lenz

Scope: Agenda of the teleconference that will take place on 24 May 2022

Action: for information

The topics on the ATMP cluster agenda were presented.

7.5.2. Introduction of the new EMA/FDA and EMA/ MHLW/PMDA liaisons

Scope: Introduction of the liaison persons

Action: for information

The CAT welcomed the EMA/FDA and EMA/ MHLW/PMDA liaisons.

7.5.3. EDQM Stakeholder consultation 5th edition Tissue and Cells Guide

CAT: Ilona Reischl

Scope: Consultation for the 5th edition of the 'Guide to the quality and safety of tissues and cells for human application'

Action: for appointment of CAT members to review the draft.

Some chapters in the 5th edition of the Tissue and Cells Guide were identified that would value CAT to review. The following CAT members will contribute: Barbara Bonamassa (chapter 18), Violaine Closson-Carella (chapter 34), Silke Dorner (chapter 41), Dariusz Sladowski, Lisbeth Barkholt. CAT members will provide comments (using the EDQM form) in advance of the deadline of 1 June to Ilona Reischl and CAT secretariat.

Note: link to download the DRAFT document of the 5th edition of the Guide in .pdf version (document reference PA/PH/TO (22)16) https://act.edqm.eu/s/6BC6pt2WmqAPfJZ

Comments should be submitted using the form referenced FORM05/TC/OC.

7.6. CAT work plan

No items

7.7. Planning and reporting

7.7.1. Marketing authorisation applications: 3-year forecast report

Scope: Update of the business pipeline report for the human scientific committees

Action: for information

CAT noted the 3-year forecast report.

7.8. Others

7.8.1. Consensus meeting on carcinogenicity of gene therapies

CAT: Martina Schüssler-Lenz

Scope: Invitation for participating as observer in a consensus meeting about assessment of potential carcinogenicity of gene therapies, to take place in October 2022.

Action: for information

The problem statement and the goal of this consensus meeting was presented: CAT agreed that it would be good for them to take part in this meeting. Carla Herberts was appointed as the CAT representative.

7.8.2. GTMPs for haemophilia, consistency in assays for factor activity

CAT: Martina Schüssler-Lenz

Scope: to address the question on how factor activities are assessed after gene therapy treatment and whether recommendations proposed by the developer in terms of treatment monitoring are consistent with EMA requirements, also with regards to the SmPC.

Action: for information

Guidance on the assay(s) to be used for treatment monitoring should be included in section 4.4 of the SmPC.

7.8.3. Adeno-associated viral (AAV) vector toxicities: regulatory considerations

CAT: Carla Herberts, Egbert Flory

Scope: Discussion paper on insertional mutagenesis and follow-up of AAV-gene therapies

Action: for discussion

It was agreed that the draft will be sent to the following CAT members for comments, before finalisation and presentation at the June CAT meeting: Lisbeth Barkholt, Claire Beuneu, Metoda Lipnik-Stangelj, Alessandro Aiuti, Alessandra Renieri, Isabel Vieira.

7.8.4. Launch of call for nominations to Quality Innovation Group

Scope: call for the expression of interest

Action: for discussion

EMA presented the composition and roles of the Quality Innovation Group (QIG). This group will aim to support the translation of innovative approaches to the design, manufacture and quality control of medicines for the benefit of patients. The group will be composed of 6 core members able to cover wide ranging aspects associated with innovation in chemical and biological active pharmaceutical ingredients (APIs), finished products, ATMPs, manufacturing facilities and GMP compliance.

CAT members were asked to consider expressing their interest to become part of the QIG. Clear support from members' agency will be needed as a high time allocation is expected for these 6 members.

CAT members can also put their name forward as ad-hoc expert to be consulted by the QIG.

8. Any other business

8.1.1. In-person meeting – practical information

Action: for information

As communicated via e-mail, the June CAT meeting will be an in-person meeting with some members remotely connected (hybrid setting).

The new system for making and managing travel and hotel bookings was presented.

Date of next CAT meeting:

15-17/06/2022

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

API: Active Pharmaceutical Ingredient

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EDQM: The European Directorate for the Quality of Medicines & HealthCare

EC: European Commission

EU NTC: European Union Network Training Centre

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MNAT: Multinational assessment team

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

QRD: Quality review of documents

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SWP: Safety Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10. List of participants

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 11-13 May 2022 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martina Schüssler-Lenz	Chair	Germany	No interests declared	
Ilona Reischl	Member (Vice-Chair)	Austria	No interests declared	
Silke Dorner	Alternate	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Evelina Shumkova	Alternate	Bulgaria	No interests declared	
Azra Selimovic	Member	Croatia	No interests declared	
Petra Sokol	Alternate	Croatia	No interests declared	
Rafaella Pontou	Member	Cyprus	No interests declared	
Isavella Kyriakidou	Alternate	Cyprus	No interests declared	
Petr Soukup	Member	Czechia	No interests declared	
Kristyna Rehorova Hradilkova	Alternate	Czechia	No interests declared	
Ebru Karakoc Madsen	Alternate	Denmark	No restrictions applicable to this meeting	
Toivo Maimets	Member	Estonia	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Maija Tarkkanen	Alternate	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Jan Mueller-Berghaus	Member (CHMP co-opted member)	Germany	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	
Maria Gazouli	Member	Greece	No interests declared	
Angeliki Rompoti	Alternate	Greece	No interests declared	
Katalin Lengyel	Member	Hungary	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Balázs Sarkadi	Alternate	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Niamh Curran	Alternate	Ireland	No restrictions applicable to this meeting	
Concetta Quintarelli	Member	Italy	No interests declared	
Barbara Bonamassa	Alternate	Italy	No restrictions applicable to this meeting	
Una Riekstina	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member (CHMP member)	Lithuania	No interests declared	
Raimondas Benetis	Alternate (to CHMP representative)	Lithuania	No interests declared	
Vlasta Zavadova	Member	Liechtenstein	No interests declared	
Guy Berchem	Alternate	Luxembourg	No participation in discussions, final deliberations and voting on:	5.2.3.
Nancy De Bremaeker	Member	Luxembourg	No interests declared	
John J. Borg	Member (CHMP member)	Malta	No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Carla Herberts	Member	Netherlands	No interests declared	
Babs Fabriek	Alternate	Netherlands	No interests declared	
Rune Kjeken	Member	Norway	No restrictions applicable to this meeting	
Maja Sommerfelt Grønvold	Alternate	Norway	No interests declared	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Marcin Kolakowski	Alternate	Poland	No interests declared	
Bruno Sepodes	Member (CHMP member)	Portugal	No interests declared	
Maria Isabel Borba Vieira	Alternate (to CHMP representative)	Portugal	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Silviu Istrate	Member	Romania	No interests declared	
Alexandrina Preda	Alternate	Romania	No interests declared	
Lukas Slovak	Member	Slovakia	No interests declared	
Katarina Vavrová	Alternate	Slovakia	No interests declared	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Suzana Vidic	Alternate	Slovenia	No participation in final deliberations and voting on:	2.11.4., 2.11.6., 2.11.7., 2.13.1. & 5.2.6.
Sol Ruiz	Member (CHMP co-opted member)	Spain	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lisbeth Barkholt	Member	Sweden	No interests declared	
Maria Luttgen	Alternate	Sweden	No restrictions applicable to this meeting	
Bernd Gänsbacher	Member	Clinicians' Representative	No interests declared	
Alessandro Aiuti	Member	Clinicians' Representative	No participation in discussions, final deliberations and voting on:	2.13.2.
Alessandra Renieri	Alternate	Clinicians' Representative	No restrictions applicable to this meeting	
Kerstin Sollerbrant	Member	Patients' Representative	No interests declared	
Lydie Meheus	Alternate	Patients' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No interests declared	
Roland Pochet	Alternate	Patients' Representative	No interests declared	
Catherine Milne	Observer/Alternate	EDQM	No interests declared	
Maria Elisabeth Kalland	Expert - via Webex	NOMA (NO)	No interests declared	
Anna Mari Lone	Expert - via Webex	NOMA (NO)	No restrictions applicable to this meeting	
Attila Sebe	Expert - via Webex	PEI DE	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Beate Mosl	Expert - via Webex	PEI DE	No restrictions applicable to this meeting	
Jurgen Scherer	Expert - via Webex	PEI DE	No interests declared	
Johannes Ovelgonne	Expert - via Webex	SAWP (NL)	No interests declared	
Serena Marchetti	Expert - via Webex	CBG-MEB (NL)	No interests declared	
Filip Josephson	Expert - via Webex	CHMP (SE)	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				